{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:31:08Z","timestamp":1747182668563,"version":"3.40.5"},"reference-count":9,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Recently, the addition of antiprogrammed cell death\u2010ligand 1 (PD\u2010L1) monoclonal antibodies, including durvalumab and atezolizumab to platinum\u2010based chemotherapy, has demonstrated clinical benefits in patients with untreated advanced small cell lung cancer (SCLC). However, these clinical trials comprised small populations of elderly patients with SCLC. Therefore, the safety of anti\u2010PD\u2010L1 immunotherapy plus platinum and etoposide in elderly patients remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective, multicenter, single\u2010arm study was designed to evaluate the safety and efficacy of durvalumab plus carboplatin and etoposide in untreated elderly patients (aged &gt;\u200975) with extensive stage (ES) SCLC. A total of 40 patients were recruited. Patients received up to four cycles of durvalumab 1500\u2009mg and carboplatin at a dose equivalent to an area under the curve of 5 on day 1, and etoposide 80\u2009mg\/m<jats:sup>2<\/jats:sup> on days 1 to 3 every 3\u2009weeks as induction treatment, followed by durvalumab maintenance treatment every 4\u2009weeks. The primary endpoint was safety as measured by adverse events according to the Common Terminology Criteria for Adverse Events version 5.0, laboratory analyses, vital signs, and physical examination. Key secondary endpoints were objective response rate, median progression\u2010free survival, 12\u2010month overall survival rate, and the completion rate for four cycles of induction chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The present study was designed to evaluate the safety of durvalumab plus carboplatin and etoposide in elderly patients with ES\u2010SCLC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.14727","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T07:41:37Z","timestamp":1668584497000},"page":"105-107","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase <scp>II<\/scp> study of durvalumab (<scp>MEDI<\/scp> 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (<scp>LOGIK<\/scp> 2003)"],"prefix":"10.1111","volume":"14","author":[{"given":"Hidenobu","family":"Ishii","sequence":"first","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine Kurume University School of Medicine  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-5856","authenticated-orcid":false,"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine Kurume University School of Medicine  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Shimose","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center Kyushu  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Kansai Medical University Hospital  Hirakata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayasu","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Kansai Medical University Hospital  Hirakata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shingu","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine Saiseikai Kumamoto Hospital  Kumamoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Respirology National Hospital Organization Kyushu Medical Center  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine Sendai Kousei Hospital  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102116"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4859"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40389-2_14"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603810"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.14727","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T15:41:45Z","timestamp":1692459705000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/1759-7714.14727"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14727","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"2022-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}